Yukina Shirai

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Akihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma et al. · Translational Lung Cancer Research · 2021 · 32 citations · Full text

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum et al. · Cancer Discovery · 2024 · 27 citations · Full text

High levels of <scp>AXL</scp> expression in untreated <scp><i>EGFR</i></scp>‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

Akihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa et al. · Cancer Science · 2022 · 20 citations · Full text

Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling

Shinji Kohsaka, Yuichiro Tada, Mizuo Ando et al. · npj Precision Oncology · 2022 · 16 citations · Full text

Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial

Takehito Shukuya, Tetsuhiko Asao, Yasushi Goto et al. · The Lancet Oncology · 2025 · 14 citations